** Test Mode **

  0.00 (USD)

This Package provides access to the entire event

Registration Header
REGISTER TODAY!

SAB Virtual R&D Event

Start Date:10/13/2021

Start Time:10:00 AM EDT

Duration:120 minutes

Abstract:

Introduction to SAB’s Unique DiversitAb™ Immunotherapy Platform

If you're already registered for the SAB Virtual R&D Event webcast, click below:

ALREADY REGISTERED?

Speakers

Eddie Sullivan, PhD

Co-Founder, President & CEO

SAB Biotherapeutics

Eddie J. Sullivan, PhD, is Co-Founder and has served as President and CEO since 2014. Dr. Sullivan has served in biopharma leadership positions for more than 25 years. Prior to joining SAB, he held the CEO role or other leadership roles in our predecessor entities, including CEO of Hematech, a subsidiary of Kyowa Hakko Kirin. During that time, he led initiatives to develop infectious disease, cancer, and autoimmune immunotherapies. In addition to raising over $250 million in capital to develop biopharmaceutical platform technologies, he has also led several successful mergers and acquisitions. A recognized thought leader in antibodies and transgenic animals, Dr. Sullivan serves on the board of directors for the Biotechnology Innovation Organization (BIO) and has served on its executive committee. He has worked with industry committees and discussion groups that have focused on animal biotechnology, regulatory framework, human immunotherapies, and global health threats. Dr. Sullivan was governor-appointed to South Dakota’s Research Commercialization Council and was Chairman of the state’s National Science Foundation-EPSCoR committee for 12 years. He also founded, served as president, and remains an advisor to the state affiliate of BIO, South Dakota Biotech. Dr. Sullivan earned two PhD’s in Health Science Administration and Reproductive Physiology from Kennedy Western University and Utah State University, respectively. In addition, he holds an MS in Reproductive Physiology and Molecular Biology from Brigham Young University and a BS in Animal Health Sciences from the University of Arizona.

Arturo Casadevall, M.D., Ph.D.

Johns Hopkins Bloomberg School of Public Health Johns Hopkins School of Medicine

The Alfred and Jill Sommer Professor and Chair W. Harry Feinstone Dept of Molecular Microbiology & Immunology Bloomberg Distinguished Professor

Tom Luke, MD

SAB Biotherapeutics

Chief Medical Officer

Christoph Bausch, PhD

EVP & Chief Operating Officer

SAB Biotherapeutics

Christoph Bausch, PhD, MBA, is EVP & Chief Operating Officer as of May 2022, overseeing all Research & Manufacturing operations of the company. Prior to his role as COO, he served as Chief Science Officer since joining SAB in April 2017, providing leadership in all areas of Research & Development, and functioned as drug development lead for a Stage 3 clinically advanced drug product. Dr. Bausch is an experienced research scientist, biotech entrepreneur and business development executive who has led the successful discovery, development, biomanufacturing, and commercialization of platform technologies in the life sciences. Previously, Dr. Bausch has served as founder and director of a molecular diagnostic company and has provided life science consulting for Keion Group, LLC. Dr. Bausch held several science-based business development positions prior to joining SAB, most recently for multi-billion-dollar global industrial biomanufacturing leader POET, LLC, where he structured strategic partnerships, prospected, and vetted new technologies and streamlined research and development activities. He also worked in both research and commercialization roles for Fortune 500 life science and high technology company Sigma-Aldrich, now MilliporeSigma. Dr. Bausch currently serves on the Board of Directors for the state affiliate of BIO, South Dakota Biotech, since 2017. He received his PhD in Microbiology at The Ohio State University, Columbus, Ohio, completed Post-Doctoral Training at the Stowers Institute for Medical Research, Kansas City, Missouri and earned an MBA from St. Louis University, St. Louis, Missouri, in addition to a BA in Biology from the University of Nebraska-Lincoln, Lincoln, Nebraska.

Michael J. Haller, MD, MS-CI

University of Florida College of Medicine

Professor and Chief Silverstein Family Eminent Scholar Pediatric Endocrinology
Share on Facebook Share on Twitter Share on Linkedin Share through Email

Sponsors

Sponsor Image
SAB Virtual R&D Event
Registration Is Closed
© 2025 Brandlive. All rights reserved.
Already Registered? Technical Requirements System Check Port Troubleshooting